Introduction {#S0001}
============

Vulvar and vaginal atrophy (VVA) is a chronic and progressive disease characterized by anatomical-functional alterations caused by aging and hypoestrogenism.[@CIT0001]

Since 2014, VVA is considered part of the genitourinary syndrome of menopause (GSM).[@CIT0001] Anatomical changes of VVA (i.e. thinning of vaginal rugae, mucosal dryness, pallor, fragility, and the presence of petechiae)[@CIT0002] develop gradually during years and do not resolve spontaneously. Hypoestrogenism leads to an atrophy of the vaginal, vulvar, urethral and bladder epithelium. Consequently, the vaginal maturation index (VMI), i.e. the ratio among three different vaginal epithelial cell types, parabasal, intermediate, and superficial, changes towards a predominance of parabasal cells. Glycogen production decreases, vaginal microbiota changes, vaginal pH increases above 4.5, and risk of vaginal infection increases.[@CIT0003],[@CIT0004] Related symptoms are dryness, dyspareunia, itching, burning, and dysuria.

In European countries, prevalence of postmenopausal VVA is around 80%.[@CIT0005],[@CIT0006] Noteworthy, 65% of women experience VVA within one year since menopause. Symptoms and signs of VVA occur also in younger women, prior to the menopause. An Italian study,[@CIT0007] performed in a cohort of women aged between 40 and 55 years observed a prevalence of VVA and of vaginal dryness of 36.8% and of 64%, respectively.

Vaginal dryness and dyspareunia are the most bothersome symptoms of VVA.[@CIT0008],[@CIT0009] These symptoms can affect sexuality, intimacy, overall pleasure, sexual satisfaction, relationship with a partner, the seeking of a new relationship and, ultimately, emotional health and woman's quality of life.[@CIT0010]--[@CIT0013]

Diagnosis of VVA can be simple: the criteria of a large multicentric Italian study (AGATA study) indicate that the concomitance of a pH\>5, sensation of vaginal dryness and an objective index at the examination (thinning of vaginal rugae, mucosal dryness, pallor, fragility, and the petechiae), is enough to make diagnosis. Anyway, diagnosis can be even easier because, as shown in epidemiological studies, all postmenopausal women with VVA suffer from vaginal dryness and dryness alone, without VVA, is present only in a small percentage of cases ranging from 3 to 10%.[@CIT0004],[@CIT0006] Thus, the only presence of vaginal dryness can be sufficient for the diagnosis of postmenopausal VVA. Vaginal dryness is also the most bothersome symptom and its presence is sufficient to start a therapy.

Therapeutic options include local and systemic hormonal and non-hormonal products, ranging from over-the-counter lubricant and moisturizers to medications such as vaginal oestrogens (cream, tablets and ring), systemic hormones and the innovative oral selective estrogen receptor modulator (SERM): ospemifene.[@CIT0014],[@CIT0015]

Therapeutic Options {#S0002}
===================

First-line therapies for women with symptomatic VVA include intercourse that can be associated with non-hormonal lubricants and regular use of long-acting vaginal moisturizers or vaginal estrogen.[@CIT0014],[@CIT0016] Therapy should be started early, before irreversible atrophic changes have occurred, and should be continued for as long as possible.[@CIT0017] Systemic hormones are an effective therapy, but they are recommended only to eligible women that beyond VVA suffer from menopausal complaints (e.g. vasomotor symptoms).[@CIT0003],[@CIT0017]

Over-the-counter vaginal lubricants and moisturizers are often prescribed as a first-line treatment and are indicated in women with a previous history of hormone-dependent cancers. Unfortunately, they may provide only a transient benefit of vaginal symptoms in comparison to local oestrogens.[@CIT0018] Vaginal lubricants are intended to be used to relieve friction and dyspareunia and are applied to the vaginal introitus before sexual intercourse. Water-based lubricants are the most common, probably because of their wide availability and low price. Unlike oil or silicone lubricants, they do not stain sheets or lingerie. According to a recent review,[@CIT0019] water-based lubricants should have an acidic pH (pH 3.8--4.5) and an osmolarity below 380 mOsm/kg. This is to preserve the vaginal microenvironment and to reduce cytopathic or irritating effects on the vaginal mucosa. Lubricants based on silicone are not absorbed by vaginal mucosa; therefore, they persist longer. A recent study reported that during sexual intercourse, silicone-based lubricants might reduce total sexual discomfort more effectively than water-based products.[@CIT0020]

Vaginal moisturizers, rather than lubricants, are locally absorbed by superficial layers, rehydrate dry mucosal tissue and have a long-term action. Specifically, the beneficial effects of vaginal moisturizers are mostly due to adhesive and buffering capacities leading to tissue water retention and vaginal pH reduction.[@CIT0021] Polycarbophil based moisturizers are as effective as vaginal oestrogen therapy in reducing postmenopausal VVA symptoms[@CIT0022],[@CIT0023] but not in improving sexual function and menopause-related quality of life.[@CIT0024]

Low dose local oestrogens, in the form of cream, tablet, or ring are all effective for VVA symptoms, with a minimal systemic absorption. Thus, vaginal oestrogen products seem to be safe with only a few adverse effects.[@CIT0025] A review including 44 published studies did not report any case of either thromboembolism or breast cancer. Nevertheless, data on long-term efficacy, risks, and tolerability are limited because most reported studies have a follow-up period of only 12 weeks.[@CIT0026]

Adherence to Local Treatments {#S0003}
=============================

Epidemiological studies have shown that most women discontinue vaginal therapy. The reason for discontinuation is that they are uncomfortable, difficult to apply, and annoying.[@CIT0009],[@CIT0013] In addition, many women claim a non-sufficient therapeutic efficacy, either for an excessive expectation or an inadequate dose-regimen.[@CIT0009] Indeed, the different types of vaginal treatments are prescribed without a clear rationale, a clear dose and scheme, and a clear indication on duration. This situation is further prompted by the absence of clear guidelines on therapeutic cycles, dosages and duration.[@CIT0009] According to a study published in 2013, many women treated with vaginal oestrogens reported missing doses at least once a month, often because of messiness when filling and inserting the applicator, general unpleasantness of the cream, the need to wash the applicator and leakage of the cream following application.[@CIT0027]

Ospemifene an Innovative Option {#S0004}
===============================

Recently, ospemifene, a new non-hormonal drug, was approved for the treatment of VVA symptoms. Ospemifene is a third-generation selective estrogen receptor modulator (SERM), that is administered orally at the dose of 60 mg daily. It was initially approved by the FDA[@CIT0028] and endorsed by the North American Menopause Society[@CIT0015] for the treatment of moderate and severe dyspareunia associated with VVA. Following the recent publication of a new clinical trial,[@CIT0029] ospemifene has been approved also for the treatment of moderate to severe vaginal dryness. In Europe, the European Medicines Agency (EMA) has approved ospemifene for the treatment of all VVA symptoms, from moderate to severe. Ospemifene is targeted for acting, as an agonist, in the vulva and vagina, without exerting major side effects in other organs. Through oestrogen receptors stimulation, ospemifene promotes proliferation of the vaginal mucosa epithelial lining.[@CIT0030] Ki-67 immunoreactivity, an index of cell proliferation, increases enormously in the basal layers of the mucosa, sampled both in the upper and the lower third of the vagina.[@CIT0030] The effect is noticeable also on vaginal collagen. Administration of ospemifene increases total collagen both in vaginal mucosa and vestibule. The preferential augmentation of type I rather than type III collagen, increases strength and resistance of vaginal tissue.[@CIT0031] Efficacy and safety of ospemifene was established in randomized, placebo-controlled, Phase II/III studies.[@CIT0032]--[@CIT0035] After only four weeks, administration of ospemifene increases superficial cells and decreases parabasal cells and vaginal pH. Concomitantly, VVA symptoms and sexuality improve.[@CIT0029],[@CIT0032]--[@CIT0035] Data on tolerability are confirmed by a recent post-hoc analysis documenting a low drop-out rate (7.6% with ospemifene and 3.8% with placebo).[@CIT0036]

At the vulva and vaginal vestibule, ospemifene reduces painful transmission of C-type nerve fibres that convey painful stimuli[@CIT0037] and exerts trophic effects. Administration of ospemifene for 20 weeks reduces urethral meatus and anterior vaginal wall prominence, stenosis of the introitus, vestibular pallor and erythema and ameliorates vulvar moisture.[@CIT0038] Modifications are associated with improvement of cotton-tipped swab testing and sexual function.[@CIT0037] Pain at intercourse decreases, while desire and arousal increase.[@CIT0039],[@CIT0040]

Ospemifene vs Vaginal Oestrogens: Safety {#S0005}
========================================

VVA is a chronic and progressive disease and it would require long-term therapy. Unfortunately, adherence to treatment is weak and many women discontinue vaginal therapy for perceived inefficacy, inconvenient administration or perceived risk.

Several studies focused on safety, specifically on the endometrium, breast and coagulation. There is no direct comparison between ospemifene and vaginal oestrogens, but, from the analysis of the literature, a historical indirect comparison can be tentatively performed ([Table 1](#T0001){ref-type="table"}). Endometrial safety of the two treatments appears to be comparable with no evidence of an increased risk of cancer. Simon et al[@CIT0041] described one event of endometrial carcinoma and one case of complex hyperplasia without atypia in postmenopausal women treated for 52-weeks with an ultra-low-dose (10-microgram) of 17β-oestradiol in vaginal tablets. In a multicentre randomized, double-blind Phase 3 study, one case of simple hyperplasia without atypia and no case of endometrial carcinoma was diagnosed three months after the last administration of a 12-week ospemifene treatment.[@CIT0035] Long-term studies, up to 52 weeks of administration, show no effect of ospemifene on the endometrium.[@CIT0033],[@CIT0042]Table 1Safety of Ospemifene and Vaginal Oestrogens on the Risk of Hormone-Dependent Cancer, Venous Thrombosis (VTE) or Cardiovascular Disease (CVD). Summary of the LiteratureOspemifeneVaginal OestrogensEndometrial CancerSafeSafeBreast CancerSafeUnclearVTESafeSafeCVDSafeSafe

Oestrogens administered into the vagina are partially absorbed, slightly increasing systemic exposure. For this reason, they are considered potentially harmful for breast cancer, although there is no evidence of an increased rate of breast cancer during or after their administration.[@CIT0043]

In vitro, ospemifene exerts anti-oestrogenic effects in the ER+ MCF-7 breast cancer cells by inhibiting, in a dose-dependent manner, the oestrogen-regulated gene expression of pS2.[@CIT0044] The same findings are observed in ovariectomized mice in vivo, where ospemifene reduces growth of MCF-7 cancer cells. In comparison to control, administration of ospemifene inhibits MCF-7 tumour growth, with a difference in volume that become significant after only 3 weeks of treatment.[@CIT0044] Similar data are shown in another study after only 4 weeks of ospemifene administration.[@CIT0045]

In vitro and in animals' results were replicated on breast tissue, collected from 26 healthy postmenopausal women undergoing reductive mammoplasty. In this model, ospemifene significantly inhibits oestrogen-induced cell proliferation.[@CIT0046] Clinical data are also reassuring.

Safety of ospemifene on breast was evaluated in a post- hoc analysis of six Phase 2 and 3 clinical trials.[@CIT0036] A total of 2200 postmenopausal women were randomized either to ospemifene or placebo for a median duration of treatment of 86 and 84 days, respectively. Breast safety was evaluated by both mammography, performed prior to treatment and after 12 months, and breast palpations performed prior to treatment, at 12 weeks, six months, and 12 months. No case of breast cancer was observed. Prevalence of adverse events such as breast tension (0.9% vs 0.6% for placebo), pain (0.6% vs 0.3%), and breast thickening (0.6% vs 0.4%), were similar in the ospemifene and placebo group (2.5% vs 2.2% for placebo).[@CIT0036] Breast density was not assessed. However, no other abnormal clinically significant mammogram findings were reported, and the prevalence of abnormal not clinically significant findings was similar between ospemifene and placebo.[@CIT0036] Based on these preclinical and clinical data, ospemifene is the only VVA therapy that stimulates oestrogen receptors at the vagina, that can be prescribed to women with a history of breast cancer, after the termination of adjuvant treatment.[@CIT0047]

Systemic estrogens[@CIT0048] and SERMS, such as raloxifene or tamoxifen,[@CIT0049]--[@CIT0051] increase the risk of venous thromboembolism (VTE). VTE is not increased by vaginal estrogens.[@CIT0043] Also ospemifene does not increase the risk of VTE. In a post-hoc analysis of 6 Phase II and Phase III studies the incidence of cardiovascular events (i.e. specifically deep vein thrombosis, cerebrovascular accidents, and cerebral haemorrhages) was shown to be very low, both in the ospemifene (0.3%) and placebo (0.1%) group.[@CIT0036] In this latter analysis, only two high-risk patients reported VTE during ospemifene, with no case of pulmonary embolism or retinal vein thrombosis. A recent post hoc analysis of five placebo-controlled clinical studies showed that, in comparison to placebo, ospemifene, up to 12 months of use, decreases fibrinogen, a known risk factor for coronary artery disease and VTE and, similarly to oral oestrogens,[@CIT0052] it increases HDL and reduces LDL.[@CIT0053] Differently from oral estrogens,[@CIT0052] ospemifene does not increase triglycerides.[@CIT0053] In a post-marketing observational analysis of the 2-year interim data of the Post Authorisation Safety Study (PASS), the incidence of VTE in the group of women receiving ospemifene (0.12%) is lower than that of women receiving other SERMS for non-neoplastic reasons (0.64%), or of women with AVV not receiving any treatment (1.23%).[@CIT0054] No increased risk of cardiovascular diseases, breast tumours, endometrial hyperplasia, or gynaecological pathologies of any kind is also observed.[@CIT0054]

Ospemifene vs Vaginal Oestrogens: Side Effects {#S0006}
==============================================

Adverse events were reported for both types of treatment, including hot flushes, vaginal discharge, muscle spasms, and headache ([Table 2](#T0002){ref-type="table"}). Among women treated with ospemifene, hot flushes were the most reported adverse event (7.5% vs 2.6% for placebo) and, although low, the most common reason for discontinuation (1.0%).[@CIT0036] Frequency and intensity of hot flushes was higher during the first four weeks of treatment and decreased subsequently with continuous use.[@CIT0055] These symptoms were observed also with vaginal oestradiol, but with an incidence below 1%.[@CIT0056]Table 2Risk of Side Effects, Discontinuation Rate, Adherence to, Satisfaction with and Overall Related Cost of Treatment with Ospemifene or Vaginal Oestrogens. Summary of the LiteratureOspemifeneVaginal OestrogensHot FlushesSlightNone/SlightVaginal DischargeSlightHighHeadacheSlightModerateLeg CrampsSlightNoneDiscontinuationSlight/ModerateHighAdherenceModerate/HighLowSatisfactionHighLowOverall Health-Related CostLowerHigher

Vaginal discharge or discomfort were reported in up to 10% of patients treated with vaginal estradiol.[@CIT0043],[@CIT0056] Simon et al reported that one of the most common treatment-related adverse events during ospemifene was vaginal discharge (3.8% vs 0.3% for placebo) but this led to treatment discontinuation only in 0.5% of patients.[@CIT0036]

As noted with other SERMs, muscle spasms are commonly reported from women using ospemifene (3.2% vs 0.9%)[@CIT0036] and are generally described as mild or moderate leg cramps. This side effect was never reported with local estrogen.[@CIT0043] Headache was reported with the same frequency during placebo or ospemifene (2.4% vs 2.4%)[@CIT0036] whereas its incidence tended to be higher ranging from 1 to 10% during the use of vaginal estrogens.[@CIT0043],[@CIT0056]

Therefore, ospemifene and local oestrogens appear to have a similar tolerability, but acceptability, adherence to treatment and discontinuation may differ as the consequence of the different pharmaceutical formulation and route of administration ([Table 2](#T0002){ref-type="table"}).

Ospemifene vs Vaginal Oestrogens: Adherence to Treatment and Satisfaction {#S0007}
=========================================================================

One study evaluating adherence to treatment with vaginal oestrogens reported that users of these formulations miss a dose at least once a month, often because of messiness, general unpleasantness of the cream, the need to wash the applicator and leakage of the cream following application.[@CIT0027] Adherence to treatment, i.e. the number of days covered by therapy out of the number of total days considered, was recently evaluated in a 12-months study, comparing ospemifene and vaginal oestrogens. The study was performed in 86,946 patients with more than one pharmacy claim for dyspareunia-related medication.[@CIT0057] Highest adherence was observed for ospemifene in comparison to non-ring local hormonal therapy e.g. conjugated oestrogen cream, oestradiol vaginal insert, and oestradiol cream (40% vs 21%; p\<0.0001). Only the ring showed a higher adherence to treatment (52%). Persistence (ie appropriate time of drug refill) was also higher for ospemifene than vaginal creams (23% vs 4--16% of vaginal cream; p\<0.0001). The ring had the highest treatment (44%) persistence. Discontinuation rate of ospemifene was 77.1%, and it was significantly lower (P\<0.0001) than that of oestradiol vaginal insert (83.6%), conjugated oestrogen cream (95.0%), and oestradiol cream (93.7%). The vaginal ring had the lowest discontinuation rate (56.4%). On these bases ospemifene can be considered superior to vaginal oestrogens but not to the vaginal ring, in terms of adherence, persistence and treatment continuation. However, the ring does not have the indication to the treatment of dyspareunia, that ospemifene has.[@CIT0058] Furthermore, health-care cost, that take into consideration the cost of the product and of medical consultations over a period of 12 months, are higher for the ring, and vaginal oestrogens, than for ospemifene. The cost of ospemifene is higher than that of local hormonal therapies, but medical consultations are less for women on ospemifene than other therapies. This indirectly supports a higher efficacy and tolerability of ospemifene vs any type of vaginal treatment, probably consequent also to a greater adherence and persistence to treatment.

Finally, when using the ring, women are concerned about inserting or removing it, about vaginal infections, hygiene and cleanliness, about the oestrogen dose administered, and about feeling it.[@CIT0027] A recent survey evaluated woman's perceptions of VVA and its therapeutic options.[@CIT0059] Symptomatic women above 45 years of age were invited to complete a survey containing 63 questions related to VVA symptoms, menopausal status, therapeutic options, way of prescription, efficacy, and acceptability. Among 1858 women that completed the survey, 7% were "current users" of a pharmaceutical therapy for VVA (including vaginal oestrogen or oral SERMS), 18% were "former users" of that therapy, 25% were current or former users of over-the-counter (OTC) products like vaginal lubricants or moisturizers, and 50% had never used any therapy ("never users"). Most recommended treatment in current or former users was vaginal oestrogen and oral hormones, but, among those who had never used any treatment, 35% stated that nothing would convince them to use hormones. Fear of using hormones and discomfort with the application make local hormonal treatments hardly accepted by women.[@CIT0059] Fear of systemic absorption and inconvenient administration of local creams, reduced adherence to treatment. Only few women (33-42%) used more than once per week vaginal oestrogens that were prescribed "continuously", and 75% of women used moisturizers and lubricants "as needed", instead of few times per week. The highest adherence to treatment was observed in women receiving the daily dose of ospemifene (59%). Satisfaction was also highest with ospemifene, reaching 67% of users. Satisfaction with lubricants and moisturizers used "as needed" was only 15% and that with vaginal oestrogens for creams, tablets or the ring ranged between 33-35%.[@CIT0059]

In conclusion, women's adherence, persistence and satisfaction with long-term treatment is higher for ospemifene than for other products.[@CIT0059] Likely, this is the consequence of a combination of effectiveness and ease of use. Unlike other local therapies, ospemifene does not need any scheme of treatment, just taking a pill per day. Adherence to treatment is favoured by the oral administration of a non-hormonal drug that avoids the inconvenience of the local application of therapies and the fear of hormones.[@CIT0059],[@CIT0060]

Conclusion {#S0008}
==========

Ospemifene is the first oral treatment for VVA that provides an alternative treatment for patients unsuitable for vaginal products or for oestrogen. Its clinical characteristics give the opportunity to propose long-term therapies for VVA that have the possibility to be followed. Ospemifene not only enlarge the number of women that can be treated for VVA, but also increases adherence and persistence to treatment.

Accordingly, in the field of the VVA therapy, ospemifene represents an innovative evolution, that can help to reduce the burden of symptoms and the consequences of postmenopausal VVA.
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